Highlights from EHA Mieloma Multiplo
|
|
- Margaret Charles
- 5 years ago
- Views:
Transcription
1 Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, Settembre 27
2 Myeloma XI TE pathway 7 R : Induction Max. Induction 2 Maintenance CTD CRD KCRD response PD SD MR PR VGPR CR R : CVD No CVD ASCT R : Lenalidomide Observation This analysis compares toxicity and response to KCRD vs triplets pre and post - ASCT Patients were ineligible for the CVD randomisation if they had achieved a CR or VGPR to induction (went straight to ASCT if eligible or maintenance if not) or had PD or SD to induction (all primary refractory received CVD). Patients were ineligible for the maintenance randomisation if they failed to respond to lenalidomide as their induction IMiD or failed to respond to all trial induction treatment, had PD or had previous or concurrent active malignancies. Dose adjustments for renal impairment and following AEs were permitted.
3 Percentage of patients Response to initial induction Lenalidomide led to deeper responses than thalidomide 79.5% %.8% KCRD (n=52) VGPR CR w/o BM CR 2 CTD (n=2) CRD (n=2)
4 Percentage of patients Response to initial induction Quadruplet KCRD led to deeper responses than either triplet % %.8% VGPR CR w/o BM CR 3 2 CTD (n=2) CRD (n=2) KCRD (n=52)
5 Myeloma XI trial outline, TE pathway 3 Induction Maintenance R CTD n=2 CRD n=2 ASCT n=23 R Lenalidomide Observation Primary endpoints: PFS and OS for each randomisation Median follow up 3.3 months Patients with a suboptimal response to Induction (<VGPR) were eligible for Induction 2. Patients with PR/MR were randomised to CVD (cyclophosphamide, bortezomib and dexamethasone) or no further therapy prior to ASCT. Patients with NC/PD all received CVD. Patients were ineligible for the CVD randomisation if they had achieved a CR or VGPR to induction (went straight to ASCT) or had PD or SD to induction. Patients were ineligible for the maintenance randomisation if they failed to respond to lenalidomide as their induction IMiD or failed to respond to all trial induction treatment, had PD or had previous or concurrent active malignancies. Dose adjustments for renal impairment and following AEs were permitted.
6 2 4 PFS (%) 8 Maintenance randomisation Significant improvement in PFS from 28 to 5 months, HR.47 4 Len Median PFS [95%CI] Obs. (n=377) 28, [24, 32] Len. (n=45) 5, [44, Inf.) Obs HR:.47 95%CI [.37,.59] Logrank P <. Est. [95%CI] Obs. (%) Len. (%) 7. [ 7.5, 8.7] 53.5 [ 48., 59.7] 38.5 [ 32.5, 45.5] 22.2 [., 3.9]. [ 8.3, 27.3] 88.9 [ 85.8, 92.2] 7.5 [.5, 7.9] 3.3 [ 57., 9.5] 53.8 [ 4.7,.9] 49.5 [ 4.2, 59.4] Time from maintenance randomisation (m) Number at risk Obs Len GH Jackson et al ASH 2 (abstract no. 43)
7 Maintenance randomisation Significant improvement in PFS from 28 to 5 months, HR.47 Subgroup Level No treat. Len. HR [ 95%CI ] P. (het) Gender Male n/n n/n.5 (.42,.74).24 3/235 9/294 Female 72/42 27/7.3 (.9,.47) Age <=5 years 49/3 9/34.47 (.3,.).9 >5 years 3/7 28/87.44 (.2,.74) ISS Stage I 2/37 37/49.42 (.28,.4).3322 Stage II 9/48 49/8.57 (.39,.82) Stage III 45/7 25/97.35 (.22,.58) t(4,4) Present 4/7 /29.44 (.9,.98).84 Absent 7/38 35/49.37 (.24,.55) del(7p) Present 8/9 9/7.4 (.4,.25).9872 Absent 7/4 37/.37 (.25,.55) q gain Present 2/44 24/9.4 (.2,.83).3 Absent 58/ 22/9.3 (.8,.5) Cytogenetic Risk SR 4/97 7/8.3 (.8,.55).855 HiR 23/4 3/.29 (.,.59) Overall UHiR 85/3778/45 /7 / (.37, (.4,.).92) Len Favours Favours Obs HR.
8 PFS (%) PFS (%) PFS (%) Maintenance randomisation Lenalidomide improved PFS irrespective of cytogenetic risk Standard risk High risk Ultra- high risk Len Median PFS [95%CI] Obs. (n=97) 28, [2, 48] Len. (n=8) NR, [5, Inf.) HR:.3 95%CI [.8,.55] Logrank P <. Len Median PFS [95%CI] Obs. (n=4) 24, [, 4] Len. (n=) 45, [45, Inf.) HR:.29 95%CI [.,.59] Logrank P = 4e-4 Len Median PFS [95%CI] Obs. (n=7) 7, [, Inf.] Len. (n=2) 9, [, 3] HR:.3 95%CI [.4,.92] Logrank P =.852 Obs Obs Obs Est. [95%CI] Obs. (%) 79. [ 7.7, 88.5] 55.2 [ 45., 7.] 45.4 [ 34.7, 59.3] 3.9 [ 8.5, 5.8] Est. [95%CI] Obs. (%) 3.5 [ 49.4, 8.5] 5.9 [ 37., 72.9] 25.4 [ 2., 53.8] 2.7 [ 3.7, 43.7] Est. [95%CI] Obs. (%) 4.2 [ 23.3, 72.7] 2.2 [ 8., 55.4]. [ 2., 57.2] 4.2 [ 23.3, 72.7] Len. (%) 97.2 [ 93.4,.] 8.2 [ 7., 92.] 7. [ 5., 88.8]. [ 52.8, 82.] Len. (%) 87.8 [ 79.7, 9.7] 78. [ 8., 9.9] 73. [ 59.5, 89.7] 48.7 [ 2.3,.] Len. (%) 5. [ 48., 88.] 3.7 [.3,.5] 8.4 [.8, 49.9] 5. [ 48., 88.] Time from maintenance randomisation (m) Number at risk 9 34 Obs Len Time from maintenance randomisation (m) Number at risk Obs Len Time from maintenance randomisation (m) Number at risk 7 2 Obs Len. 2 High risk (HiR) - presence of any one of t(4;4), t(4;), t(4;2), del(7p), or gain(q). Ultra-high risk (UHiR) - presence of more than one lesion. Standard risk (SR) - absence of any of the above lesions.
9 2 4 PFS (%) 8 Interaction between induction and maintenance The best outcomes are associated with lenalidomide maintenance induction and 8 Median PFS [95%CI] CTD/Obs (n=87) 4, [37, 5] CTD/Len (n=22) 58, [49, Inf.) CRD/Obs (n=9) 34, [32, 42] CRD/Len (n=23) NR, [5, Inf.) CRD - Len Logrank P < Time from randomisation (m) CTD/Obs = CTD induction, randomised to observation. CTD/Len = CTD induction, randomised to lenalidomidemaintenance. CRD/Obs = CRD induction, randomised to observation. CRD/Len = CRD induction, randomised to lenalidomidemaintenance.
10
11
12
13 Methods MM patients enrolled in the RV-MM-COOP-55 (EMN2/HO95 MM; NCT287) Newly diagnosed 5 years MRD assessement in patients achieving suspected CR before lenalidomide maintenance N: 7 N: 459 N: VCD CTX + PBSC harvest R HDM-2 N: 5 R2 2 VRD N: 444 Lenalidomide maintenance 4 VMP No cons Pre Maint CR: complete response, N: number of patients ; V, bortezomib; C, cyclophosphamide; D, dexamethasone; CTX: cyclophosphamide 2-3g/mq, PBSC: peripheral stem cell collection, HDM: high dose melphalan 2mg/mq, R, lenalidomide; M, melphalan; P, prednisone; Cons: consolidation, Maint: maintenanc; Maint Maint Maint Maint EVERY MONTHS UNTIL CLINICAL RELAPSE Cavo M et al. ASH 2; Abstract 73. Sonneveld P. et al. ASH 2; Abstract 292
14 % of patients Results MRD status at pre-maintenance Sub-analysis on MRD positive patients at pre-maintenance who had a second MRD evaluation > year of Lenalidomide 24% 7% MRD positive Pre maintenance MRD positive MRD negative % 52% LEN maintenance -2 months
15 % of patients Results MRD status during maintenance Sub-analysis on MRD positive patients at pre-maintenance who had a second MRD evaluation > year of Lenalidomide 4% 8-24 months 8 44% -2 months MRD positive Pre maintenance % LEN maintenance MRD negative
16 Results Progression free Survival: Median Follow-Up from MRD enrollement of 33 Months. 3-yr PFS 77% Progression-free survival N = 3 MRD negative MRD positive Median PFS NR 38 months 52%. Numbers at risk MRD Negative MRD Positive HR (95% CI) P value.33 (.2.53) Months
17
18
19
20 Study Design Multicenter, randomized, open-label, active-controlled, phase 3 study Key eligibility criteria RRMM prior line of therapy Prior bortezomib exposure but not refractory R A N D O M I Z E : DVd (n = 25) Daratumumab ( mg/kg IV) Every week: Cycles -3 Every 3 weeks: Cycles 4-8 V:.3 mg/m 2 SC on Days, 4, 8, and of Cycles -8 d: 2 mg PO-IV on Days, 2, 4, 5, 8, 9,, and 2 of Cycles -8 Vd (n = 247) V:.3 mg/m 2 SC on Days, 4, 8, and of Cycles -8 d: 2 mg PO-IV on Days, 2, 4, 5, 8, 9,, and 2 of Cycles -8 D only Every 4 weeks: Cycles 9+ Obs only Primary endpoint PFS Secondary endpoints TTP OS ORR, VGPR, CR MRD Time to response Duration of response Exploratory Time to next therapy Stratification factors ISS (I, II, and III) Number of prior lines ( vs 2 or 3 vs >3) Prior bortezomib (no vs yes) Cycles -8: repeat every 2 days Cycles 9+: repeat every 28 days Premedication for the DVd treatment group consisted of dexamethasone 2 mg, acetaminophen, and an antihistamine MRD evaluation Assessed at suspected CR and at and 2 months following the first treatment dose for patients who maintain CR ISS, International Staging System; DVd, daratumumab, bortezomib, and dexamethasone; IV, intravenous; V, bortezomib; SC, subcutaneously; d, dexamethasone; PO, orally; Vd, bortezomib and dexamethasone; D, daratumumab; Obs, observation; PFS, progression-free survival; TTP, time to progression; OS, overall survival; ORR, overall response rate; VGPR, very good partial response; CR, complete response; MRD, minimal residual disease. 2
21 % surviving without progression Updated Efficacy: ITT P < No. at risk Vd 247 DVd 25 HR:.3 (95% CI, ; P <.) Months DVd Median:.7 mo Vd Median: 7. mo 8 ORR = 84% CR CR 9% ORR = 3% 29% a CR % Updated VGPR 2% a Primary Updated VGPR 29% Primary DVd (n = 24) Vd (n = 234) CR 9% Note: Primary analysis based on median follow-up of 7.4 months Duration of response: 8.9 months for DVd versus 7. months for Vd 9% reduction in risk of progression for DVd versus Vd 9.-month improvement in median PFS for DVd versus Vd Responses continue to deepen HR, hazard ratio; CI, confidence interval; PR, partial response; scr, stringent complete response.. Palumbo A, et al. N Engl J Med. 2;375(8): a P <. for DVd versus Vd. 2
22 % surviving without progression Updated Efficacy: Prior Line 8-month PFS a P = No. at risk Vd 3 DVd 22 HR,.9 (95% CI,.2-.29; P <.) Months % 2% Vd DVd Median: not reached 5 2 Median: 7.9 mo 4 ORR = 9% CR ORR = 74% 2% CR 4% b CR % Updated VGPR 7% b Primary Updated VGPR 42% Primary DVd (n = 9) Vd (n = 9) CR % Note: Primary analysis based on median follow-up of 7.4 months 8% reduction in risk of progression/death for DVd versus Vd Deeper responses with longer follow-up a Kaplan-Meier estimate. b P <. for DVd versus Vd.. Palumbo A, et al. N Engl J Med. 2;375(8):
23 % surviving without progression CASTOR: PFS by Cytogenetic Risk Status a 8 High risk DVd n = 44 Vd n = 5 4 DVd standard risk mpfs, mo HR (95% CI) P value.45 (.25-.8).53 No. at risk Vd standard risk DVd standard risk Vd high risk DVd high risk 2 Vd standard risk Months Vd high risk DVd high risk Standard risk mpfs, mo HR (95% CI) P value DVd n = 23 Vd n = (.8-.37) <. Adding DARA to standard of care prolongs PFS regardless of cytogenetic risk a ITT/biomarker-risk-evaluable analysis set: patients in the ITT population with both RNA and DNA results available. 23
24 POLLUX: Study Design Multicenter, randomized (:), open-label, active-controlled phase 3 study DRd (n = 28) RRMM Key eligibility criteria prior line of therapy Prior lenalidomide exposure, but not refractory Creatinine clearance 3 ml/min Stratification factors No. prior lines of therapy ISS stage at study entry R A N D O M I Z E : Daratumumab mg/kg IV Qw in Cycles -2, q2w in Cycles 3-, then q4w until PD R 25 mg PO Days -2 of each cycle until PD d 4 mg PO 4 mg weekly until PD Rd (n = 283) R 25 mg PO Days -2 of each cycle until PD d 4 mg PO 4 mg weekly until PD Cycles: 28 days Primary endpoint PFS Secondary endpoints TTP OS ORR, VGPR, CR MRD Time to response Duration of response Statistical analyses Primary analysis: ~77 PFS events Prior lenalidomide Pre-medication for the DRd treatment group consisted of dexamethasone 2 mg a, acetaminophen, and an antihistamine a On daratumumab dosing days, dexamethasone was administered 2 mg premed on Day and 2 mg on Day 2. RRMM, relapsed and/or refractory multiple myeloma; ISS, international staging system; DRd, daratumumab/lenalidomide/dexamethasone; IV, intravenous; qw, once weekly; q2w, every 2 weeks; q4w, every 4 weeks; PD, progressive disease; R, lenalidomide; PO, oral; d, dexamethasone; Rd, lenalidomide/dexamethasone; PFS, progression-free survival; TTP, time to progression; OS, overall survival; ORR, overall response rate; VGPR, very good partial response; CR, complete response; MRD, minimal residual disease. 24
25 % surviving without progression Overall response rate, % Updated Efficacy 8 8-month PFS* 7% Median: not reached DRd 9 8 ORR = 93% 23 P <. ORR = 7% 4 2 HR:.37 (95% CI,.28-.5; P <.) 49% Median: 7.5 months Rd CR: 4% a 8 CR: 2% 2 23 VGPR: 78% a DRd (n = 28) Rd (n = 27) VGPR: 45% scr CR VGPR PR No. at risk Months Rd DRd Median follow-up: 7.3 (range, -24.5) months Responses continue to deepen in the DRd group with longer follow-up Note: PFS: ITT population; ORR: response-evaluable population. * Kaplan-Meier estimate; a P <. for DRd vs Rd. 25
26 % surviving without progression POLLUX: PFS by Cytogenetic Risk Status a 8 High risk DRd n = 28 Rd n = 37 DRd standard risk mpfs, mo DRd high risk HR (95% CI).53 (.25-.3) 4 Rd standard risk Rd high risk P value.92 2 Standard risk DRd n = 33 Rd n = 3 Patients at risk Rd standard risk DRd standard risk Rd high risk DRd high risk Months mpfs, mo HR (95% CI) P value NR (.2-.47) <. Adding DARA to Rd prolongs PFS regardless of cytogenetic risk mpfs, median PFS; NR, not reached. a ITT/biomarker-risk-evaluable analysis set: patients in the ITT population with both RNA and DNA results available. 2
27 MRD negative, % Proportion of MRD-negative Patients at 4, 5, and Thresholds MRD negative, % *** 3.X POLLUX *** 4.2X *** 4.X 35 *** 4.5X CASTOR ** 5.X * 4.X Sensitivity threshold DRd Rd 5 *** P <. ** P <.5 * P < Sensitivity threshold Daratumumab in combination with standard of care significantly improved MRD-negative rates at all thresholds DVd 2 Vd 4 P values calculated using likelihood-ratio chi-square test.
28 Patients progression free and alive (%) Rd MRD DRd MRD Patients progression free and alive (%) PFS According to MRD Status at 5 POLLUX CASTOR Vd MRD DVd MRD 8 8 DRd MRD + DVd MRD + 4 Rd MRD Vd MRD Patients at risk Rd MRD negative DRd MRD negative Rd MRD positive DRd MRD positive Months Patients at risk Vd MRD negative DVd MRD negative Vd MRD positive DVd MRD positive Months Lower risk of progression in MRD-negative patients PFS benefit in MRD-positive patients who received daratumumab-containing regimens versus standard of care
29 MRD-negative patients POLLUX: MRD in Patients of High Cytogenetic Risk Status ( 5 ) % surviving without progression 35 3 MRD-negative rates PFS P =.9 DRd MRD negative 8 per risk group, % a DRd MRD positive Rd MRD positive DRd n = 28 High risk Rd n = 37 No. at risk Rd MRD negative DRd MRD negative Rd MRD positive DRd MRD positive Months In POLLUX, high-risk patients treated with DARA who were MRD negative remained progression free a Percentage of patients within a given risk group and treatment arm. 29
30 MRD-negative patients CASTOR: MRD in Patients of High Cytogenetic Risk Status ( 5 ) % surviving without progression MRD-negative rates P =.8 PFS DVd MRD negative per risk group, % a DVd MRD positive 2 DVd n = 44 High risk Vd n = 5 No. at risk Vd MRD negative DVd MRD negative Vd MRD positive DVd MRD positive Months Vd MRD positive 2 In CASTOR, high-risk patients treated with DARA who were MRD negative remained progression free a Percentage of patients within a given risk group and treatment arm. 3
31 Background Anti-apoptotic proteins BCL-2 and MCL- promote multiple myeloma (MM) cell survival Venetoclax is a selective, orally available small molecule BCL-2 inhibitor and bortezomib can indirectly inhibit MCL- 2 When combined, venetoclax can enhance the activity of bortezomib in MM cell lines and xenograft models 2. Roberts AW et al. N Eng J Med 2; 374: Punnoose E et al. Mol Cancer Ther 2;(5):
32 Dosing and Enrollment Patients received 5 2 mg venetoclax per designated dose escalation cohorts Cycles 8 Designated Cohort Dose Cycles 9 Designated Cohort Dose Cycles 2+ Days 35 at Monotherapy Day Dexamethasone and bortezomib (.3 mg/m 2 SC) Dexamethasone (2 mg, PO) Dosing cycle 2 days for cycles 8 and 35 days for cycles 9+ Enrollment by Dose Cohort Dose (mg) Total DE SE Total DE + SE n DE, dose escalation cohorts; SE, safety expansion cohort (8 mg) As of 9Aug2 32
33 Objective Responses in All Patients and Those Non- Refractory and Refractory to PIs and IMiDs Percentage of patients ORR=92% 8% ORR=82% ORR=7% 22% 4% % 5% 27% ORR=57% 7% 23% 38% ORR=32% 4% 4% 27% 9% 24% 24% 25% 4% 3% All patients (N=) Non-refractory (n=37) Refractory (n=28) Non-refractory (n=22) Refractory (n=42) Prior proteasome inhibitors (PIs) Prior immunomodulatory drugs (IMiDs) As of 9Aug2 33
34 P e r c e n ta g e o f P a tie n ts BCL2 Gene Expression and Clinical Response s C R /C R V G P R P R T im e to P r o g r e s s io n O R R 9 4 % B C L 2 H ig h 8 33% 7 5 B C L 2 L o w O R R 5 9 % 7% % % % 37% B C L 2 H ig h ( n = 8 ) B C L 2 L o w ( n = 2 7 ) M o n th s s in c e firs t d o s e P a tie n ts a t ris k P a tie n ts a t ris k BCL2 quantitation using ddpcr performed on CD38-selected bone marrow mononuclear cells collected at baseline. BATTing was used to estimate a threshold of BCL2 to provide optimum selection of patients likely to have a response. As of 9Aug2 34
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationIn-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups
In-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) in transplant eligible
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationMultiple Myeloma New Trials and New Drugs. Rafat Abonour, M.D.
Multiple Myeloma New Trials and New Drugs Rafat Abonour, M.D. Treatment Combinations Then and Now NEW VD Rev/Dex CyBorD VTD VRD CDR SCT VD/VRD Lenalidomide Bortezomib Bortezomib Lenalidomide Thalidomide
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationClínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain. ClinicalTrials.gov Identifiers: NCT and NCT
Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated With Daratumumab in Combination With Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationStudy Objectives: GMMG MM5
Study Objectives: GMMG MM5 1.) Demonstration of non-inferiority of VCD induction therapy compared to PAd induction therapy with respect to response rate (very good partial remission or better; response
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationSTUDY DESIGN. VMP 6-week cycles, total of 9 cycles. Figure 2. Alcyone study design. Countries housing study sites are shaded in gold.
TPS8608 A Randomized Open-label Study of Bortezomib, Melphalan, And Prednisone (VMP) Versus Daratumumab () Plus VMP in Patients With Previously Untreated Multiple Myeloma (MM) Who Are Ineligible for High-dose
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationDARA Monotherapy Studies
Usmani, SZ. Blood. 26. http://dx.doi.org/.82/blood-26-3-752. Lokhorst HM, et al. N Engl J Med. 25;373(3):27-29. Lonial S, et al. Lancet. 25. I DARA Monotherapy Studies Baseline Characteristics Median (range)
More informationRelapsed Myeloma Sequencing Treatments
Relapsed Myeloma Sequencing Treatments Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Professor of Medicine Harvard Medical School Disclosures Consultant /Advisory Board: Celgene,
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationTherapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz
Therapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz 15.6.218 Newly Diagnosed Multiple Myeloma Transplant Eligible NDMM TE VCD is preferable to
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationMultiple Myeloma Transplant and Non-transplant Modalities
Multiple Myeloma Transplant and Non-transplant Modalities Sikander Ailawadhi, MD Associate Professor of Medicine Division of Hematology-Oncology Mayo Clinic, Jacksonville, Florida 15 th Annual Miami Cancer
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationMaking Sense of Myeloma Treatment Advances
Making Sense of Myeloma Treatment Advances Webinar 1, May 17, 217 Updates From the 16th International Myeloma Workshop and the American Association for Cancer Research 217 Annual Meeting Speakers Moderator:
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationMULTIDISCIPLINARY MULTIPLE MYELOMA CARE
MULTIDISCIPLINARY MULTIPLE MYELOMA CARE Regional Lecture Series Leveraging a Multidisciplinary Approach to Multiple Myeloma Care Leveraging a Multidisciplinary Approach to Multiple Myeloma Care Abhinav
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationThe TOURMALINE-MM1 study: results and expert insights
The TOURMALINE-MM1 study: results and expert insights Professor Faith Davies UAMS Myeloma Institute, Arkansas, USA This educational meeting was organised and fully funded by Takeda UK Ltd. Takeda medicines
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationMultiple Myeloma. Dr. Janet MacEachern BA, MD, FRCP(C) Grand River Regional Cancer Center Kitchener, Ontario
Multiple Myeloma Dr. Janet MacEachern BA, MD, FRCP(C) Grand River Regional Cancer Center Kitchener, Ontario Disclosures Relationships with financial sponsors: Grants/Research Support: n/a Speakers Bureau/Honoraria:
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationWhat New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center
What New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center 1 JOSEPH TUSCNO, MD WHAT S NEW IN HEMATOPOEITIC STEM CELL TRANSPLANTATION? RELEVANT FINANCIAL RELATIONSHIPS
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationMultiple Myeloma Highlights: 2016 ASH Annual Meeting Patient Webinar
2016 ASH Annual Meeting Patient Webinar January 11, 2017 1 Welcome and Introductions Anne Quinn Young, MPH Vice President, Development and Strategic Partnerships Multiple Myeloma Research Foundation 2
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationAdvances in the Management of Myeloma Parameswaran Hari, MD
Advances in the Management of Myeloma Parameswaran Hari, MD Medical College of Wisconsin Milwaukee, WI What is the standard? Induction/Transplant/Maintenance UPDATED OS DATA from CALGB 100104 & IFM 2005-02
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationNuove indicazioni e nuove terapie nel mieloma mul2plo
Nuove indicazioni e nuove terapie nel mieloma mul2plo Paola Tacche* Seràgnoli Ins3tute of Hematology Bologna University School of Medicine Mul2ple factors contribute to the clonal evolu2on and treatment
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationMeu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationDigging Deeper Updates from ASH Interviews with Dr. Berinstein, Dr. Cheson, Dr. Connors, Dr. LeBlanc, Dr. Owen, and Dr.
P E R S P E C T I V E S I N O N C O L O G Y Number 3 April 217 Digging Deeper Updates from ASH 216 INSIDE THIS ISSUE MULTIPLE MYELOMA Novel Agent and New Therapy Combinations Provide Effective Treatment
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More information